Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CERE-110: Adeno-Associated Virus Delivery of NGF · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CERE-110: Adeno-Associated Virus Delivery of NGF | GENETIC | CERE-110 2.0 x 10\^10 vg, CERE-110 1.0 x 10\^11 vg, CERE-110 2.0 x 10\^11 vg |
Inclusion Criteria: * Alzheimer's disease as determined by NINCDS/ADRDA criteria. * Score of ≤ 4 on a modified Hachinski Ischemia Scale * Mini-Mental State Exam (MMSE) score in the range of 16 to 28, inclusive * No significant neurological or medical abnormalities contraindicating surgery, MRI/PET ...
Top 20 of 24 competitors
CERE-110 is an investigational gene therapy being studied for the treatment of mild to moderate Alzheimer's Disease. It delivers nerve growth factor (NGF) via an adeno-associated virus vector. The therapy is designed to potentially slow or prevent the degeneration of cholinergic neurons, which are affected in Alzheimer's Disease.
CERE-110 is being developed by Sangamo Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol SGMO. The company is focused on gene therapy and genome editing technologies.
CERE-110 is in Phase 1 clinical development. It has completed a Phase 1 trial in patients with mild to moderate Alzheimer's Disease. The drug is investigational and has not been approved by the FDA.
CERE-110 has been studied in one clinical trial, identified as NCT00087789. This Phase 1 trial, titled 'CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease,' was conducted in the United States and enrolled 10 participants aged 50 years and older. The trial has been completed.
Yes, CERE-110 is also known as Adeno-Associated Virus Delivery of NGF. This name reflects its mechanism of using an adeno-associated virus vector to deliver nerve growth factor (NGF) to the brain.